Saar Gill
Saar Gill
Nepoznata afilijacija
Potvrđena adresa e-pošte na
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 ImmunotherapyAlternative Splicing of CD19 Enables Resistance to CART-19
E Sotillo, DM Barrett, KL Black, A Bagashev, D Oldridge, G Wu, ...
Cancer discovery 5 (12), 1282-1295, 2015
Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma
MP Chao, AA Alizadeh, C Tang, JH Myklebust, B Varghese, S Gill, M Jan, ...
Cell 142 (5), 699-713, 2010
Human chimeric antigen receptor macrophages for cancer immunotherapy
M Klichinsky, M Ruella, O Shestova, XM Lu, A Best, M Zeeman, ...
Nature biotechnology 38 (8), 947-953, 2020
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
M Ruella, DM Barrett, SS Kenderian, O Shestova, TJ Hofmann, ...
The Journal of clinical investigation 126 (10), 3814-3826, 2016
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell
M Ruella, J Xu, DM Barrett, JA Fraietta, TJ Reich, DE Ambrose, ...
Nature medicine 24 (10), 1499-1503, 2018
Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells
S Gill, SK Tasian, M Ruella, O Shestova, Y Li, DL Porter, M Carroll, ...
Blood, The Journal of the American Society of Hematology 123 (15), 2343-2354, 2014
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
JA Fraietta, KA Beckwith, PR Patel, M Ruella, Z Zheng, DM Barrett, ...
Blood, The Journal of the American Society of Hematology 127 (9), 1117-1127, 2016
Going viral: chimeric antigen receptor T‐cell therapy for hematological malignancies
S Gill, CH June
Immunological reviews 263 (1), 68-89, 2015
CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia
SS Kenderian, M Ruella, O Shestova, M Klichinsky, V Aikawa, ...
Leukemia 29 (8), 1637-1647, 2015
NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects
JA Olson, DB Leveson-Gower, S Gill, J Baker, A Beilhack, RS Negrin
Blood, The Journal of the American Society of Hematology 115 (21), 4293-4301, 2010
Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia
MY Kim, KR Yu, SS Kenderian, M Ruella, S Chen, TH Shin, AA Aljanahi, ...
Cell 173 (6), 1439-1453. e19, 2018
Chimeric antigen receptor T cell therapy: 25 years in the making
S Gill, MV Maus, DL Porter
Blood reviews 30 (3), 157-167, 2016
Macrophage-Based Approaches for Cancer ImmunotherapyMacrophage-Based Approaches for Cancer Immunotherapy
NR Anderson, NG Minutolo, S Gill, M Klichinsky
Cancer research 81 (5), 1201-1208, 2021
Decade-long leukaemia remissions with persistence of CD4+ CAR T cells
JJ Melenhorst, GM Chen, M Wang, DL Porter, C Chen, MKA Collins, ...
Nature 602 (7897), 503-509, 2022
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
NR Mathew, F Baumgartner, L Braun, D O'Sullivan, S Thomas, ...
Nature medicine 24 (3), 282-291, 2018
Efficacy and safety of hydroxychloroquine vs placebo for pre-exposure SARS-CoV-2 prophylaxis among health care workers: a randomized clinical trial
BS Abella, EL Jolkovsky, BT Biney, JE Uspal, MC Hyman, I Frank, ...
JAMA internal medicine 181 (2), 195-202, 2021
Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells
S Gill, AE Vasey, A De Souza, J Baker, AT Smith, HE Kohrt, M Florek, ...
Blood, The Journal of the American Society of Hematology 119 (24), 5758-5768, 2012
Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell DysfunctionDeath Receptor–impaired tumors cause CAR T-cell failure
N Singh, YG Lee, O Shestova, P Ravikumar, KE Hayer, SJ Hong, XM Lu, ...
Cancer discovery 10 (4), 552-567, 2020
The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell LymphomaCombination of CART19 and …
M Ruella, SS Kenderian, O Shestova, JA Fraietta, S Qayyum, Q Zhang, ...
Clinical Cancer Research 22 (11), 2684-2696, 2016
Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia
SK Tasian, SS Kenderian, F Shen, M Ruella, O Shestova, M Kozlowski, ...
Blood, The Journal of the American Society of Hematology 129 (17), 2395-2407, 2017
Sustav trenutno ne može provesti ovu radnju. Pokušajte ponovo kasnije.
Članci 1–20